Description:

Size: 100 microliters

Catalog no.: GENTObs-11776R-A594

Price: 489 EUR

Product details

Subcellular locations

N/A

Swiss Prot

N/A

Gene ID

7337

Modification site

None

Applications

IF(IHC-P)

Target Protein/Peptide

UBE3A/E6-AP

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Conjugated

Alexa conjugate 1

Conjugated with

ALEXA FLUOR® 594

Applications with corresponding dilutions

IF(IHC-P)(1:50-200)

Clonality

Polyclonal Antibody

Clone

Polyclonal Antibodies

Purification method

Purified by Protein A.

Group

Polyclonals and antibodies

Type

Conjugated Primary Antibody

Other name

Anti-UBE3A/E6-AP Polyclonal

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Host organism

Rabbit (Oryctolagus cuniculus)

Also known as

UBE3A/E6-AP Polyclonal Antibody

Properties

For facs or microscopy Alexa 1 conjugate.

Modification

No modification has been applied to this antibody

Specificity

This antibody reacts specifically with UBE3A/E6-AP

Antigen Source

KLH conjugated synthetic peptide derived from human UBE3A/E6-AP

Cross reactive species

Human (Homo sapiens), Mouse (Mus musculus), Rat (Rattus norvegicus)

Storage

Water buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at 4°C for 12 months.

Description

This antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.

About

Polyclonals can be used for Western blot, immunohistochemistry on frozen slices or parrafin fixed tissues. The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera.

Cross Reactive Species details

No significant cross reactivity has been observed for this antibody for the tested species. However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species.

Advisory

Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody, thus reducing its reactivity, specificity and sensitivity. For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube. Prior to use briefly centrifuge the vial to gather all the solution on the bottom.

Synonyms

ANCR; Angelman syndrome; AS; CTCL tumor antigen se37 2; E6 AP; E6AP antibody E6AP ubiquitin protein ligase; E6AP ubiquitin protein ligase; E6AP ubiquitin-protein ligase; EPVE6AP; HPVE6A; Human papilloma virus E6 associated protein Angelman syndrome; Human papilloma virus E6 associated protein; Human papillomavirus E6-associated protein; NY REN 54 antigen; NY REN 54 antigen; Oncogenic protein associated protein E6 AP; Oncogenic protein associated protein E6AP; Oncogenic protein-associated protein E6-AP; Renal carcinoma antigen NY REN 54; Renal carcinoma antigen NY-REN-54; UBE 3A; Ube3a; UBE3A protein; UBE3A_HUMAN; Ubiquitin protein ligase E3A; Ubiquitin-protein ligase E3A.

Background information

E6-associating protein is a component of the ubiquitin-mediated proteolytic pathway, which selectively targets proteins for degradation by the 26S proteasome. Ubiquitin (Ub) is directly conjugated to protein substrates by the transfer of Ub from an E2 ubiquitin conjugating enzyme to the target protein. This conjugation is facilitated by the enzymatic activity of E3 ubiquitin ligase family members such as E6-AP. Several substrates of E6-AP have been identified and include the tumor suppressor protein p53 and the mammalian homolog of Rad23, HHR23A. Previous studies have indicated that E6-AP associates with the human papillomavirus E6 oncogene, which complexes with p53 and thereby potentiates E6-AP mediated ubiquitination of p53. Genetic mutations that impair E6-AP activity result in the accumulation of p53 in the cytoplasm, and, in many instances, these mutations are associated with the development of the rare neurodevelopmental disorder Angelman syndrome (AS), which is characterized by severe motor dysfunction and mental retardation.